2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1392

The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes
Abstract Number: 2442

The Relationship Between Fatigue and Disease Activity as Determined by Different Indices in Patients with Psoriatic Arthritis (PsA)
Abstract Number: 735

The Relationship Between Gastrointestinal Symptoms and Severity and Whole Gut Transit in Patients with Systemic Sclerosis
Abstract Number: 2732

The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations
Abstract Number: 197

The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application
Abstract Number: 1172

The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging
Abstract Number: 1145

The Representation of Skin Tones in Images of Patients with Lupus Erythematosus
Abstract Number: 1130

The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine
Abstract Number: 823

The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study
Abstract Number: 334

The Role of a ‘Treat-to-Target’ Approach on Long-term Renal Outcomes in Patients with Gout
Abstract Number: 80

The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model
Abstract Number: 2896

The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
Abstract Number: 2858

The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model
Abstract Number: 996

The Role of Flip in Differentiation and Survival of Synovial Tissue Resident Macrophages
Abstract Number: 1095

The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].